-arrestins also mediate noncanonical signaling via ERK1/2 and other kinases, which, for the GLP-1R, is linked to insulin secretion and inhibition of beta cell apoptosis 14,36
Food and Drug Administration announced that it is requesting the removal of suicidal behavior and suicidal ideation warnings from certain GLP-1 receptor agonist medications
Beyond fatty acid transport, L-carnitine has been studied for exercise recovery, reduced muscle damage biomarkers (creatine kinase, lactate dehydrogenase), and cardiovascular function through improved myocardial energy metabolism
The modified peptide's extended activity window theoretically amplifies this concern
The retatrutide availability timeline depends on ongoing clinical trials and regulatory review: Current status: Multiple phase 3 trials (TRIUMPH program) ongoing Phase 3 primary completion: Expected through mid-year NDA submission: Eli Lilly expected to submit to FDA in late future FDA review period: Approximately 10 months after submission Estimated approval: Potentially late next year at earliest Commercial launch: Could follow shortly after approval It is important to note that Eli Lilly has not announced an official filing timeline
If our team members are making decisions with the mindset of putting the patient first, I always have their back